The cost of migraine to the NHS in England: a retrospective cohort study using electronic health record data from Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)
Abstract
Abstract Objectives To quantify healthcare resource utilization (HCRU) and associated direct medical costs of migraine among adults in England compared with general population controls. Methods This retrospective cohort study used linked primary and secondary healthcare data (Clinical Practice Research Datalink Aurum [CPRD] and Hospital Episode Statistics [HES]) in England. Migraine cases (adults newly diagnosed with migraine between 1-Jan-2017 and 31-Mar-2019) and general population controls were matched on age, sex, ethnicity, practice region, Index of Multiple Deprivation 2019, and baseline depression and cardiovascular disease. All-cause HCRU and costs were estimated for cases and compared with controls using Fisher’s Exact and Mann-Whitney U tests. Subgroup analyses were conducted by migraine treatment group (acute only, preventative only, acute and preventative, no treatment). Results A total of 62,143 migraine cases and matched controls were identified, of which 76.2% (n = 47,376) were female and the mean [SD] age at index was 39.8 [15.5] years. All-cause direct medical costs per-person per-year (pppy) were approximately 81% greater (p < 0.0001) in those with migraine (median [Q1, Q3]: £492 [£205, £1,149]) than controls (£272 [£101, £716]). The acute and preventative treatment subgroup had the highest all-cause direct costs pppy (£925 [£430, £2,046]). Conclusion Overall, patients diagnosed with migraine contribute a substantially larger cost burden on the healthcare…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 47,376 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.